A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies

Obinutuzumab (GA101) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed to address the need for new therapeutics with improved efficacy in patients with lymphocytic leukemia and lymphoma of B-cell origin. Obinutuzumab has a distinct mode of action r...

Descripción completa

Detalles Bibliográficos
Autores principales: Tobinai, Kensei, Klein, Christian, Oya, Naoko, Fingerle-Rowson, Günter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331088/
https://www.ncbi.nlm.nih.gov/pubmed/28004361
http://dx.doi.org/10.1007/s12325-016-0451-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331088/
https://www.ncbi.nlm.nih.gov/pubmed/28004361
http://dx.doi.org/10.1007/s12325-016-0451-1

Ejemplares similares